Adding to its spree of out-licensing deals, Hanmi has convinced oncology leader Roche to partner in developing its early phase pan-RAF (rapidly accelerated fibrosarcoma) inhibitor, HM95573, in a deal worth up to US$910 M including an upfront payment of US$80M. The deal came a day before Boehringer Ingelheim announced that it will return the rights to Hanmi’s cancer drug, olmutinib, in the wake of severe toxicity reported by the South Korean Ministry of Food and Drug Safety.